Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Rationale For almost 30 years, CIDP treatment consists of intravenous immunoglobulins (IVIg), corticosteroids or plasma exchange. Unfortunately, both IVIg and corticosteroids are considered treatments that suppress the disease rather than cure the disease, meaning that most patients starting on IVIg will require long-term maintenance treatment to avoid a relapse. Discovery of pathogenic antibodies in some patients with CIDP and the undisputed efficacy of anti- CD20 therapy in other demyelinating diseases such as multiple sclerosis has provided new arguments to introduce anti-CD20 therapy (such as rituximab) as a treatment modality in CIDP. In addition, rituximab (RTX) if now often used for/in treatment refractory CIDP cases and a recent review of retrospective studies has suggested efficacy in this group of patients. However, RTX efficacy data on new patients starting IVIg or patients who are on maintenance IVIg treatment is largely lacking. As RTX treatment has shown to lead to long-term remission in various auto-immune diseases, the hypothesis is that RTX can prevent ongoing need of IVIg treatment in CIDP.

Objective The primary objective of this study is to assess whether adding RTX to a limited period of IVIg induction treatment leads to long-term remission and discontinuation of IVIg, reducing the inconvenience of regular Ig infusions and related health care costs. Other objectives are to explore the feasibility of introducing rituximab as alternative maintenance treatment in patients with CIDP in patients who experience a relapse after at least 6 months after last RTX treatment (long term follow-up).

Main trial endpoints The investigators will include two groups of patients, namely untreated patients (Group 1) and immunoglobulin (Ig)-dependent patients (Group 2, see below, trial population). Primary outcome for both Group 1 and 2 is remission at 52 weeks after start of RTX. For Group 1, remission is defined as sustained improvement, without the need for further treatment. Improvement will be defined as decrease in disability by at least the minimal clinical important difference (MCID) on the adjusted INCAT (aINCAT) disability scale and/or the Inflammatory-Rasch Overall Disability Scale (IRODS).

Sustained is defined as no deterioration after maximal improvement achieved in week 13 to 26. For Group 2, remission is defined as no change in disability (MCID) between start of Ig withdrawal and week 52. Patients will be considered as a treatment failure if they do not meet the criteria for remission, or if they receive any immunomodulatory treatment for CIDP except RTX after discontinuation of induction treatment (Group 1), or withdrawal of maintenance Ig treatment (Group 2).

Other trial endpoints These will include various impairment measures, pain, fatigue, quality of life and adverse events. Endpoints will be assessed at 52 and 104 weeks, or earlier if a preliminary endpoint (relapse) is reached within the first year.

Trial design Multicentre, observational single arm study where patients will be participating for two years, including a 52 week intervention period and another 52 weeks for follow-up.

Trial population The study population will consist of two patient groups. In the first group (Group 1) new patients will be included, who are starting IVIg induction treatment. In the second group (Group 2) patients will be included who are already on maintenance IVIg or subcutaneous Ig (SCIg) treatment, and who are likely to be Ig dependent. Ig dependency will be defined as having wear-off symptoms before next IVIg infusion or SCIg administration suggesting active disease, patients with a documented failed IVIg/SCIg withdrawal attempt in the last year, or who required recent increase of IVIg/SCIg Protocol synopsis version 1.2, d.d. 15-07-2024 dosage with objective improvement.

Interventions Both groups will receive RTX, consisting of two infusion of 1000 mg per day two weeks apart (baseline) and a single infusion of 500 mg at 6 months. Because treatment effect of RTX can only be expected after 2-3 months, patients from Group 1 will initially receive concomitant IVIg induction treatment which will be stopped after 3-4 months. In Group 2, Ig will be tapered after 12 weeks by 25% during 3 infusions (IVIg) or in 2 months (SCIg). RTX will be administered at the hospital, as well as the first dose of IVIg of Group 1 (standard treatment), after which the IVIg can be administered at home.

Ethical considerations This study is considered of moderate risk. Side effects associated with RTX are well documented, and most often include infusion related reactions such as fever, hypertension, rash, tachycardia and fatigue and a moderately increased chance of infections The side effects associated with the combination of RTX and IVIg have not been previously studied in CIDP, however, these individual drugs have been studied extensively, and there is plenty of experience of combining these drugs in clinical practices in conditions such as myasthenia gravis, myositis and encephalitis. Therefore, the investigators do not expect unforeseen adverse events. For Group 2, there is a risk of a relapse if RTX does not lead to remission, in which case IVIg/SCIg will need to be restarted. Regular IVIg/SCIg withdrawals to assess Ig dependency are however part of standard care. Total follow-up of the study is 104 weeks. Follow-up hospital visits will be scheduled at 2, 8, 13, 26, 39, 52, 78 and 104 weeks. Unscheduled visits (including visits during relapses) can be scheduled at any time. For Group 1, potential benefits are related to the initial combination of IVIg and RTX: fast improvement and long-term remission, and possibly a higher proportion of patients improving as not all patients respond to IVIg. For Group 2, potential benefit is a long-term remission, thereby avoiding regular IVIg/SCIg infusions, associated side effects and high health care costs.